GTCDxᵀᴹ Monkey Anti-AAV2 Antibody ELISA Kit

Name: GTCDxᵀᴹ Monkey Anti-AAV2 Antibody ELISA Kit
SKU: DEIASL347Y
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum

Species Reactivity

Monkey

Detection Method

iELISA

Intended Use

The Anti-AAV2 ELISA is used as an analytical tool for qualitative determination of antibodies to AAV2 in serum.

Contents of Kit

No.	Components	Size	Storage Conditions
1	AAV2 Capsid Coated Microtiter Plate	12×8 wells	2-8°C
2	Negative Control, ready to use	1 × 1 mL	2-8°C
3	Anti-AAV2 Positive Control, ready to use	1 × 1 mL	2-8°C
4	Anti-IgG Conjugate, 100×	1 × 0.12 mL	2-8°C
5	Sample Diluent, ready to use	1 × 50 mL	2-8°C
6	Wash Buffer, 20 × concentrate	1 × 50 mL	2-8°C
7	TMB Substrate, ready to use	2 × 6 mL	2-8°C
8	Stop Solution, ready to use	1 × 7 mL	2-8°C
9	Instruction Manual	1

Storage

1. All reagents should be stored at 2°C to 8°C for stability.
2. All the reagents and wash solutions should be used within 12 months from manufacturing date.
3. Before using, bring all components to room temperature (18-25°C). Upon assay completion ensure all components of the kit are returned to appropriate storage conditions.
4. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

General Description

Researchers have used AAV-based vectors in pre-clinical research and in clinical trials in which AAV-based vectors have demonstrated a good safety profile. AAVs have also demonstrated lasting therapeutic gene expression following a single treatment in preclinical and clinical studies.
Recombinant vectors based on AAV2 (rAAV2) have been, or are currently being, used in a number of Phase I/II clinical trials, and thus far, no serious adverse events, much less cancer of any type have ever been observed or reported. Furthermore, the use of rAAV2 vectors has led to clinical efficacy in the potential gene therapy of at least three human diseases: Leber's congenital amaurosis (LCA), aromatic L-amino acid decarboxylase deficiency (AADC) and choroideremia.
One of the major challenges in AAV-based gene therapy is the presence of circulating anti-AAV neutralizing antibodies, which can pre-exist in patients and may prevent successful gene transfer. High levels of circulating anti-AAV neutralizing antibodies can develop after a single administration of gene therapy and can prevent successful gene transfer in patients.

Citations